JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer
Status:
Not yet recruiting
Trial end date:
2024-11-17
Target enrollment:
Participant gender:
Summary
This is an open-label phase Ib/II clinical study to evaluate the safety, tolerability,
pharmacokinetics and initial efficacy of JS004 injection combined with toripalimab and with
or without standard chemotherapy in patients with advanced lung cancer